TD Cowen reinstates coverage on Tempus AI with 'buy' after Ambry deal
TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...
Tempus Completes Acquisition of Ambry Genetics
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...
Tempus AI shares rise 5% pre-market on continued momentum, Ambry Genetics acquisition
Shares of Tempus AI , Inc. (NASDAQ:TEM) climbed 5% in pre-open trading Tuesday following the completion of its acquisition of ...
Why Tempus AI (TEM) Is Jumping Today
Tempus AI (TEM) is soaring 13% today after investment bank TD Cowen reinstated coverage of the shares with a Buy rating. TEM ...
Tempus AI (TEM) Acquires Ambry Genetics in $600M Precision Medicine Push
We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at where Tempus AI, Inc.
Tempus AI: In Vogue, But Better To Wait For Some Retracement
Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.
Tempus AI's Flywheel Effect: Monetizing Data In Precision Medicine
Tempus AI claims to have a one-stop-shop, with a flywheel platform that becomes better with each new client. See why I rate TEM stock a buy.
Justin Baldoni’s lawyer previously represented man suing actor over ‘Five Feet Apart’ script
Travis Flores accused Baldoni of copyright infringement and breach of contract over the movie, which he claimed ripped off ...
Why Tempus AI (TEM) Is Skyrocketing Now
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward ...
360dx1d
TD Cowen Reinstates Buy Rating for Tempus AI, Raises Price Target to $74
The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.